Charles River Laboratories | CRL - Current Liabilities


Charles River Laboratories reported $1.09B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Agilent USD 2.27B 35M Mar/2026
Align Technology USD 1.91B 14.16M Mar/2026
Bio-Rad Laboratories USD 917M 400M Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Cardinal Health USD 41.99B 1.33B Mar/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Cigna USD 52.61B 3.74B Mar/2026
Concord Medical Services Hldg CNY 2.45B 1.12B Jun/2025
CVS Health USD 86.41B 2.29B Mar/2026
Danaher USD 7.46B 653M Mar/2026
Dentsply International USD 1.21B 136M Mar/2026
Elevance Health USD 44.25B 1.06B Jun/2026
Humana USD 21.51B 5.16B Mar/2026
Illumina USD 1.57B 19M Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Intrexon USD 23.02M 38K Jun/2024
IQVIA Holdings USD 8.33B 9M Mar/2026
Laboratory Of America USD 2.64B 182.5M Mar/2026
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
McKesson USD 67.02B 1.11B Mar/2026
Merck EUR 9.35B 307M Mar/2026
Mettler Toledo International USD 1.11B 89.76M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Quest Diagnostics USD 2.18B 101M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
UnitedHealth USD 114.12B 773M Mar/2026
Veradigm USD 230.31M 22.78M Dec/2022
Waters USD 1.24B 11.8M Dec/2025
West Pharmaceutical Services USD 674M 19.1M Mar/2026